China's Jiangsu Hengrui Pharmaceuticals said on Monday it has agreed to license the global rights of its HRS-9821 drug and 11 ...

"Longer follow-ups after the pandemic are needed to investigate persistent brain aging effects and their long-term ...

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

"Uveal Melanoma Market Insight, Epidemiology and Market Forecast - 2034"The uveal melanoma treatment market is experiencing ...

With the stock's last traded price at Rs 3,081, GlaxoSmithKline Pharmaceuticals has experienced a notable decline, positioning it among the top losers on the Nifty Midcap 150 index.

Laura Jensen was tapped to help Pharma Solutions reimagine their go-to-market strategies and direct-to-patient models.

Adrenocortical Carcinoma Market Forecast upto 2034—Insights into Emerging Therapies and Market Trends | DelveInsight The adrenocortical carcinoma market in the 7MM is anticipated to boost during the ...

Pharma giant Glaxosmithkline, which has major operations in Upper Providence and West Point, is partnering with China-based ...

Hengrui Pharma partners with GSK to develop 12 innovative medicines, boosting globalization for Hengrui and expanding GSK's oncology and RI&I pipeline.

Sydnie Mason laughs with her lab partner at the SNC GlaxoSmithKline Summer Immersion Experience in Biotech, a biotechnology ...